ArticleJournal of ovarian research2025
Mechanistic role of the KRTAP5-AS1/miR-199b-5p/CYP19A1 axis in polycystic ovary syndrome pathogenesis.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundPolycystic ovary syndrome (PCOS) pathogenesis involves dysregulated granulosa cell function, but molecular mechanisms remain unclear.
methodsHigh-throughput RNA sequencing was performed on ovarian granulosa cells from 6 PCOS patients and 3 controls to identify differentially expressed mRNAs. Bioinformatics analyses including ceRNA network construction predicted the KRTAP5-AS1/miR-199b-5p/CYP19A1 regulatory axis, which was experimentally validated through dual-luciferase reporter assays. qRT-PCR confirmed the expression patterns of these molecules in expanded clinical cohorts (38 PCOS vs. 30 controls), with Pearson correlation analysis examining relationships between gene expression and clinical parameters. Using the KGN granulosa cell line, functional studies included: (1) ELISA quantification of estradiol production; (2) proliferation assessment via CCK-8 and colony formation assays; and (3) apoptosis evaluation by flow cytometry and Bax/Bcl-2 protein analysis. These experiments were performed following both gain-of-function (overexpression) and loss-of-function (shRNA knockdown) manipulations of KRTAP5-AS1 and miR-199b-5p.
resultsThrough RNA sequencing of ovarian granulosa cells from 6 PCOS patients and 3 controls, we identified CYP19A1 as significantly upregulated in PCOS. Expanded validation in 38 PCOS vs. 30 controls confirmed elevated CYP19A1 and reduced miR-199b-5p in PCOS, with KRTAP5-AS1 showing negative correlation to miR-199b-5p and positive to CYP19A1. Clinically, CYP19A1 upregulation correlated with poor embryo quality, elevated testosterone, AMH, BMI, and infertility duration, while miR-199b-5p levels associated positively with embryo quality. In KGN granulosa cells, miR-199b-5p overexpression suppressed CYP19A1 expression and estradiol synthesis, whereas KRTAP5-AS1 overexpression alleviated this suppression via competitive miR-199b-5p binding. Functional studies demonstrated that miR-199b-5p overexpression combined with KRTAP5-AS1 knockdown inhibited proliferation, promoted apoptosis, and reduced estradiol production, while opposite manipulations reversed these effects.
conclusionsOur findings reveal that KRTAP5-AS1 modulates granulosa cell dysfunction in PCOS through the miR-199b-5p/CYP19A1 axis, highlighting miR-199b-5p as a potential therapeutic target for PCOS-related ovarian dysfunction and endocrine abnormalities. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.